NCT Number: NCT00990626
Seroquel XR in Schizophrenia Relapse Prevention
The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improve the relapse prevention in schizophrenic outpatients
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–70 year
Sex eligibility
All sexes
Study type
Observational
Primary location
Research Site, Baja, Hungary
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Schizophrenic outpatients on at least 600 mg Seroquel XR treatment for at least 1 month
Exclusion criteria
- Severe cerebro- and cardiovascular disease, severe hepatic impairment, gravidity
Treatment and study plan
Primary outcomes
-
Rate of patients remained relapse free after 6 months of treatment
Secondary outcomes
-
Adherence rate of patients
-
Quality of Life (QoL )
Sponsors and collaborators
Lead sponsor
AstraZeneca
Industry
Registry information
Important dates
- Study start
- 2009
- Primary completion
- 2010
- Study completion
- 2010
- First posted
- Oct 7, 2009
- Registry last updated
- Nov 17, 2010
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.